Maxime Verhoeven

24 Chapter 2 Table 1 Baseline patient and disease characteristic of included studies. First author, publication year, reference Design Age in yrs. (SD) Female (%) RF+ (%) HAQ score (SD) Symptom duration in weeks (SD) DAS28 (SD) single csDMARD- initiating strategy N in single csDMARD- initiating strategy Remission- induction strategy N in remission- induction strategy Time of assess- ments in yrs. Treatment characteris- tics (both arms) b/tsDMARD based remission-induction strategy versus single csDMARD-initiating strategy without GC bridging Atsumi, 2016 11 RCT 49 (11) 81 95 1.1 (0.7) 16 (11) 5.5 (1.2) MTX+PBO 157 CZP+MTX 159 1 T2T Bijlsma, 2016 4 RCT 54( § ) 67 72 1.2 (0.6) 4( § ) 5.2 (1.1) MTX+PBO 108 TCZ+MTX TCZ+PBO 106 103 0.5 T2T Burmester, 2016 12 RCT 50 (13) 78 89 1.6 (0.7) 26 (26) 6.7 (1.0) MTX+PBO 289 TCZ+MTX TCZ+MTX (reduced dose) TCZ+PBO 291 290 292 1 T2T Dougados, 2014 13 RCT 52 (14) 72 § § 34 (22) 6.5 (1.0) MTX 178 ETN+MTX 213 1 T2T Emery, 2017 14 RCT 51 (14) 77 97 1.6 (0.6) 12 (17) 6.7 (0.9) MTX+PBO 213 CZP+MTX 655 1 T2T Horslev- Petersen, 2014 15 RCT 55( § ) 66 72 1.1( § ) 12( § ) 5.6 § MTX+PBO 91 ADA+MTX 89 1 T2T Keystone, 2017 16 RCT § § § § § MTX+PBO 210 BARI + MTX BARI 215 159 1 T2T Keystone, 2017a 17 RCT 52 (14) 84 73 1.5 (0.7) 39 (44) 6.3 (0.9) MTX+PBO 257 ADA+MTX 268 0.5 T2T Kirchgsner, 2018 18 RCT 48 (12) § § § § § PBO 15 INF 15 1 no adjustments INF until 22w Nam, 2014b 19 RCT 48 (13) 76 55 1 (0.4) 28( § ) 4.1 (1.1) MTX+PBO 55 ETN+MTX 55 1 T2T Smolen, 2015 20 RCT 49 (13) 78 97 1.7 (0.7) 26 (29) 6.3 (1.0) MTX+PBO 209 ADA+MTX 210 1 T2T Stamm, 2018 21 RCT 53 (14) 73 35 0.9 (0.7) 10 (2) 4.9 (1.4) MTX+PBO 36 INF+MTX 38 1 step up MTX Takeuchi, 2014 22 RCT 54 (13) 81 84 1.2 (0.8) 16 (21) 6.6 (1.0) MTX+PBO 163 ADA+MTX 171 0.5 T2T